Member Info for solstace

who are themselves part of the 160bn Dollar Behemoth Danaher Corp!!!! They don't come any bigger for an AIM Tiddler!!!

Mmm yeah of course it is lol GDR just entered a supply agreement with a 6bn dollar U.S company covering the U.S.A and Europe!!!!

at 14.15 U.S.A waking up............................

will be a shake and a half at some point and then a good solid rise into close!!!

Americans love American companies and the companies that American companies collaborate with! Look and you will see!!!

14.30 :-) About to get very busy here!!!

BGF RNS you are out!!!!

Ha ha ha ha ha ha ha! Where do these idjiots come from???

I was looking for a Beckman stock price, ticker was BEC but I guess it's now under the DHR ticker.............

https://www.asktraders.com/analysis/genedrive-shares-gain-after-beckman-coulter-partnership-announcement/

I posted straight away I missed the date!!!!!!!!!!!!!!!!!!!!!!

Forget that just noticed the date lol

https://www.nyse.com/trader-update/history#9917

More than 275,000 Beckman Coulter systems operate in both Diagnostics and Life Sciences laboratories around the world.

Big Bed over at Danaher corp, GDR right in the middle tucked up between Beckman and Cytivia :-)

https://www.mybeckman.uk/about-us?utm_source=google&utm_medium=cpc

https://www.biopharma-reporter.com/Article/2020/04/01/GE-Healthcare-Life-Sciences-becomes-Cytiva

Will see GDR hit new highs this year!!

This afternoon or tomorrow for BGF Tr1 IMOP

All LAB's running Beckman Coulter Biomek PCR automated test stations will be using this test, this year!!! It's a huge BoooM from here on!!!

BC deal will be HUGE for GDR! How many LAB's will be going fully automated? Its the way forward! How many Biomek machines globally?? Fully launched in TWO weeks from now puts GDR into the ££'s, this is just as big as NCYT now imop. GLA

The Access SARS-CoV-2 IgG II quantitative assay is the latest addition to Beckman Coulter’s suite of testing solutions designed to provide valuable information to clinicians in their fight against COVID-19. Beckman Coulter also recently launched an automated SARS-CoV-2 antigen test in the US under Policy C of the FDA’s emergency use authorisation (EUA) program. While several point of care (POC) antigen tests are now available to help increase testing beyond current levels, POC tests come with workflow challenges when scaled to large patient populations.